ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Stock Information for ASLAN Pharmaceuticals Limited
Loading
Please wait while we load your information from QuoteMedia.